VTVT - vTv Therapeutics Inc Stock Price, Fair Value and News

$13.53-0.34 (-2.45%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VTVT Price Action

Last 7 days

-10.3%

Last 30 days

-2.2%

Last 90 days

5.2%

Trailing 12 Months

54.3%

VTVT RSI Chart

VTVT Valuation

Market Cap

43.2M

Price/Earnings (Trailing)

-2.36

Price/Sales (Trailing)

19.29

EV/EBITDA

-0.07

Price/Free Cashflow

-1.84

VTVT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VTVT Fundamentals

VTVT Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

VTVT Earnings

Earnings (TTM)

-18.3M

Earnings Growth (Yr)

28.12%

Earnings Growth (Qtr)

7.66%

VTVT Profitability

EBT Margin

-1120.37%

Return on Equity

-121.97%

Return on Assets

-42.41%

Free Cashflow Yield

-54.21%

VTVT Investor Care

Shares Dilution (1Y)

22.00%

Diluted EPS (TTM)

-4.53

VTVT Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	5.0M	5.0M	2.0M	2.0M
2021	5.8M	5.2M	4.6M	4.0M
2020	0	0	0	6.4M
2019	11.3M	10.6M	7.3M	2.8M
2018	2.3M	4.8M	8.1M	12.4M
2017	288.0K	119.0K	96.0K	291.0K
2016	845.0K	917.0K	822.0K	634.0K
2015	1.3M	1.0M	776.5K	519.0K
2014	1.1M	1.3M	1.4M	1.5M
2013	0	0	0	976.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About vTv Therapeutics Inc

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

CEO	Mr. Paul J. Sekhri M.Sc., MSc
WEBSITE	https://vtvtherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	13

vTv Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for vTv Therapeutics Inc? What does VTVT stand for in stocks?

VTVT is the stock ticker symbol of vTv Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of vTv Therapeutics Inc (VTVT)?

As of Tue Dec 24 2024, market cap of vTv Therapeutics Inc is 44.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VTVT stock?

You can check VTVT's fair value in chart for subscribers.

Is vTv Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VTVT is over valued or under valued. Whether vTv Therapeutics Inc is cheap or expensive depends on the assumptions which impact vTv Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTVT.

What is vTv Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 24 2024, VTVT's PE ratio (Price to Earnings) is -2.42 and Price to Sales (PS) ratio is 19.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VTVT PE ratio will change depending on the future growth rate expectations of investors.